Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Pioglitazone and Metformin Reduce Liver Fat in Diabetes
Last updated July 22, 2026
Key finding
The level of gamma-GT decreased in both groups before and after treatment, which was statistically significant.
The study investigated the effects of combined treatment with pioglitazone and metformin on liver fat in type 2 diabetes patients, finding a significant reduction in liver fat content.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study investigated the effects of combined treatment with pioglitazone and metformin on liver fat in type 2 diabetes patients, finding a significant reduction in liver fat content.
Clinical relevance
Reducing liver fat is crucial for managing type 2 diabetes, as excess fat in the liver can lead to further complications. This study suggests that combining pioglitazone with metformin may offer a beneficial approach for patients struggling with liver fat accumulation, potentially improving their overall health outcomes.
Keep in mind
Limited sample size may affect generalizability. No long-term follow-up data provided. Potential confounding factors not fully controlled.
Published in
Journal Reference
Publication details and source links for this paper.
Fu J, Xiao W, Gao X, et al. Combined Treatment with Pioglitazone and Metformin Reduces Liver Fat in Type 2 Diabetes Patients. Journal of Diabetes Research. 2023;2023:2044090. doi:10.1155/2023/2044090
Main Effects
Gamma-GT levels decreased by 15.57 IU/L (p = 0.001) in both treatment groups.
Combined treatment with pioglitazone and metformin effectively reduced liver fat content.
No significant differences in blood lipid levels between the treatment and control groups.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Metformin, Pioglitazone and Blood lipid, Body weight, Waist circumference, and 3 more.
This study contributes evidence to
Primary intervention
Metformin
Primary outcomes
- Blood lipid
- Body weight
- Waist circumference
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
6
Evidence pairs
351
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Metformin Therapies and Body Composition
Related evidence
Evidence relationship
Metformin Therapies and Body Weight
Save evidence
Evidence topic
Adverse Events and Safety
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Gamma-GT levels significantly decreased by 15.57 IU/L (p = 0.001).
- No significant changes in body weight or waist circumference were observed.
- Serious adverse events occurred in 10% of the control group and 6.67% of the treatment group (p = 0.74).
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Patients with elevated liver fat content.
Keep in Mind
- Results may not apply to populations outside the study sample.
- Short duration of the study limits understanding of long-term effects.
- Further research is needed to confirm findings and explore mechanisms.
Between the Lines
- Limited sample size may affect generalizability.
- No long-term follow-up data provided.
- Potential confounding factors not fully controlled.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and Body Weight, Metformin Therapies and Body Composition.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Metformin Therapies → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
View evidenceMedications
Metformin Therapies → Body Composition
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
View evidenceMedications
Metformin Therapies → Blood lipid
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Composition Evidence Hub
All studies measuring Body Composition
2 studies
outcome_hubMeasures Body Composition as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
2 studies
outcome_hubMeasures Body Weight as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
2 studies
intervention_hubContributes to Metformin Therapies evidence base.
Blood lipid Evidence Hub
All studies measuring Blood lipid
1 studies
outcome_hubMeasures Blood lipid as a key outcome.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Metformin and Body weight
Intervention: MetforminOutcome: Body weight
2 results
All studies on Metformin and Waist circumference
Intervention: MetforminOutcome: Waist circumference
2 results
All studies on Metformin
Intervention: Metformin
2 results
All studies measuring Body weight
Outcome: Body weight
2 results
All studies measuring Waist circumference
Outcome: Waist circumference
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Metformin Therapies affect body weight?
Strong Evidence
Metformin Therapies appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve body composition?
Strong Evidence
Metformin Therapies appears to improve Body Composition.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Waist circumference
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Pioglitazone improve liver fat content?
Moderate Evidence
Pioglitazone may improve Liver fat content.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Liver fat content
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Does Pioglitazone improve serum γ-gt?
Emerging Evidence
Pioglitazone appears to improve Serum γ-GT.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Serum γ-GT
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Vildagliptin and Metformin Improve Glycemic Control in Type 2 DiabetesEarly use of effective therapies may improve diabetes outcomesPremeal metformin improves postmeal glucose control in diabetes.Metformin may reduce prandial insulin needs in pregnant women with type 1 diabetesPemvidutide improves liver fat and body weight in MASLD
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.